临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1802929-43-6

PRN1371

CAS号:1802929-43-6
分子式: C26H30Cl2N6O4 分子量: 561.46
产品形式: free base
研发状态: Terminated
研发用途: Solid Tumors; Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
研究机构: Principia Biopharma a Sanofi Company
研发日期: October 28 2015
研发阶段: Phase 1
PRN1371 is an irreversible covalent FGFR1-4 kinase inhibitor, with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, 2, 3, 4 and CSF1R, respectively.

CAS: 1802220-02-5

Repotrectinib (TPX-0005)

CAS号:1802220-02-5
分子式: C18H18FN5O2 分子量: 355.37
产品形式: free base
研发状态: Recruiting
研发用途: Locally Advanced Solid Tumors; Metastatic Solid Tumors
研究机构: Turning Point Therapeutics Inc.; Zai Lab (Shanghai) Co. Ltd.
研发日期: March 7 2017
研发阶段: Phase 1 : Phase 2
Repotrectinib (TPX-0005) is a novel ALK/ROS1/TRK inhibitor with the IC50 values of 1.01 nM for WT ALK, 1.26 nM for ALK(G1202R), and 1.08 nM for ALK(L1196M); also a potent SRC inhibitor (IC50 5.3 nM).

CAS: 1801765-04-7

TNO155

中文名称:(3S,4S)-8-(6-氨基-5-((2-氨基-3-氯吡啶基-4-基)硫代)吡嗪-2-基)-3-甲基-2-氧杂-8-氮杂螺[4.5]癸-4-胺
CAS号:1801765-04-7
分子式: C18H24ClN7OS 分子量: 421.95
产品形式: Free base
研发状态: Withdrawn
研发用途: Renal Impairment
研究机构: Novartis Pharmaceuticals; Pharmaceutical Research Associates; Novartis
研发日期: March 19 2025
研发阶段: Phase 1
TNO155 is an inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2 /src homology region 2 domain phosphatase /PTPN11) with IC50 of 0.011 µM. TNO155 has potential antineoplastic activity.

CAS: 1801344-14-8

Emavusertib (CA-4948)

CAS号:1801344-14-8
分子式: C24H25N7O5 分子量: 491.50
产品形式: Free Base
研发状态: Terminated
研发用途: Myelodysplastic Syndromes; Anemia
研究机构: University of Leipzig; Curis Inc.
研发日期: January 1 2022
研发阶段: Phase 2
Emavusertib (CA-4948) is a potent and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4/FMS-like Tyrosine Kinase 3 (IRAK4/FLT3) with anti-tumor activity.

CAS: 18010-40-7

Bupivacaine HCl

中文名称:盐酸布比卡因
CAS号:18010-40-7
分子式: C18H28N2O.HCl 分子量: 324.89
产品形式: Hydrochloride
研发状态: Not yet recruiting
研发用途: Video-assisted Thoracic Surgery (VATS)
研究机构: University of Utah
研发日期: May 1 2024
研发阶段: --
Bupivacaine HCl binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells, used for treating cardiac arrhythmias.

CAS: 1800487-55-1

OT-82

CAS号:1800487-55-1
分子式: C26H21FN4O 分子量: 424.47
产品形式: Free Base
研发状态: Unknown status
研发用途: Lymphoma; Lymphoma Non-Hodgkin; Lymphoma B-Cell; Lymphoma T-Cell; Lymphoma Follicular; Lymphoma Peripheral T-Cell; Lymphoma Hodgkin
研究机构: Oncotartis Inc.
研发日期: July 29 2019
研发阶段: Phase 1
OT-82 is a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with average IC50s of 13.03 nM in non-HP cancer cells and 2.89 nM in HP cancer cells, respectively.